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Pain is one of the commonest symptoms in clinical 
practice. Nearly, half of all patients who visit a physician 
have a primary complain of any type of pain. Person who 
is experiencing the pain can only describe it properly. It is 
a very subjective experience. 
Pain is a part of the body's defence system which protect 
our body from the painful stimulus and avoid that harmful 
situation in the future.
1
 It is an important part of human life 
and vital to healthy survival. People with congenital 
insensitivity to pain have reduced life expectancy.
2
 Most 
pain resolves promptly once the painful stimulus is 
removed and the body has healed, but sometimes pain 
persists despite removal of the stimulus and apparent 
healing of the body; and sometimes pain arises in the 
absence of any detectable stimulus, damage or disease.
3 
Humans have always tried to understand why they 
experience pain and how that pain comes about. While 
pain was previously thought to be the work of evil spirits, 
it is now understood to be a neurological signal. However, 
the perception of pain is not absolute and can be impacted 
by various factors including surrounding painful stimulus, 
the visual perception of the stimulus and an individual's 
personal history with pain. 
Pain may significantly impair the ability to perform normal 
daily activities, such as dressing oneself comfortably as 
well as sleeping comfortably. This impairment must be 
taken into account when designing treatment programs for 
our patient. The psychological effect of these impairments 
on patient can be of great significance. A person with 
chronic pain can suffer from depression, anxiety, anger or 
loss of self esteem. Social consequences are also important 
to consider as a result of change in physical functioning. 
The suffering that a person experiences; relationship with 
family and friends; intimacy, including sexual activity, all 
will often become worse. People feel isolated and this 
isolation also contributes to the impact of chronic pain on 
patient. Finally, from societal point of view, it is important 
to recognize that chronic pain disables more people and 
contributes more to healthcare costs than cancer and heart 
disease combined. So, control and management of pain is 
essential for smooth and easy going life.    
Analgesics are drugs that selectively relieve pain without 
blocking the conduction of nerve impulses, markedly 
altering sensory perception, or affecting consciousness.
4
 
These drugs act in various ways on peripheral and central 
nervous systems. In selecting analgesics, type and severity 
of pain, and response to other medication determines the 
choice of agent. In pharmaceutical research, the 
investigation of compounds for treating both acute and 
chronic pain is a great challenge.
5
 Depending on their 
efficacy, they are divided into two groups- Non-narcotic 
analgesics (for treating mild to moderate pain, some 
having antipyretic actions) and narcotic/opioid analgesics 
(for treating severe pain and may sometimes produce 
dependence). Other modalities of pain management 
include tricyclic antidepressants and anticonvulsants, 
interventional procedures, physical therapy, physical 
exercise, application of ice and/or heat, and psychological 
measures, such as biofeedback and cognitive behavioral 
therapy. 
Flupirtine is the prototype of a new class of drug: the 
selective neuronal potassium channel opener (SNEPCO) 
which  is used as an analgesic for acute and chronic pain, 
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in moderate to severe cases.
6
  It is unique as a non-opioid, 
non-NSAID and non-steroidal analgesic. However, it lacks 
anti-inflammatory effect which limits its use in 
inflammatory conditions such as rheumatism, rheumatic 
fever and osteoarthritis. 
The portions of the nervous system responsible for the 




1. Afferent pathways 
2. CNS 
3. Efferent pathways 
               Afferent pathways terminate in the dorsal horn of 
the spinal cord (1st afferent neuron). 2nd afferent neuron 
creates spinal part of afferent system. The portion of CNS 
involved in the interpretation of the pain signals are the 
limbic system, reticular formation, thalamus, 
hypothalamus and cortex.  
                The efferent pathways, composed of the fibers 
connecting the reticular formation, midbrain, and 
substantia gelatinosa, are responsible for modulating pain 
sensation.  
   There are four basic processes involved in pain 
sensation.
9





There are three categories of noxious stimuli: 
A. Mechanical (pressure, swelling, abscess, incision, 
tumour growth) 
B. Thermal (burn, scald) 
C. Chemical (excitatory neurotransmitter, toxic 
substance, ischaemia, infection) 
These noxious stimuli cause a release of chemical 




• Substance P 
• Potassium 
• Histamine 
These chemical mediators activate and/or sensitise the 
nociceptors to the noxious stimuli. In order for a pain 
impulse to be generated, an exchange of sodium and 
potassium ions (de-polarisation and re-polarisation) occurs 
at the cell membranes. This results in an action potential 
and generation of a pain impulse. The pain impulse is then 
transmitted from the spinal cord to the brain stem and 
thalamus via two main nociceptive ascending pathways. 
These are the spinothalamic pathway and the 
spinoparabrachial pathway. 
Perception of pain is the end result of the neuronal activity 
of pain transmission and where pain becomes a conscious 
multidimensional experience. The multidimensional 
experience of pain has affective-motivational, sensory-
discriminative, emotional and behavioural components. 
The multiple and complex pathways involved in the 
modulation of pain are referred to as the descending 
modulatory pain pathways (DMPP) and these can lead to 
either an increase in the transmission of pain impulses 
(excitatory) or a decrease in transmission (inhibition). 
The exact mechanisms involved in the pathophysiology of 
chronic pain are complex and remain unclear. It is believed 
that following injury, rapid and long-term changes occur in 
parts of the CNS that are involved in the transmission and 
modulation of pain.
10 
CHEMICAL STRUCTURE-   
Flupirtine is an aminopyridine which systematic (IUPAC) 
name is ethyl {2-amino-6-[(4-fluorobenzyl)amino]pyridin-
3-yl}carbamate. Its synthesis is a four-step process starting 
from 2,6-dichloro-3-nitro-pyridine.
11
 Its Formula is 
C15H17FN4O2 and molecular  mass is 304.32 g/mol. 
 
Structure of Flupirtine 
HISTORY 
Flupirtine (as flupirtine maleate ) was first synthesized by 
Homburg, Degussa Pharma Group of Frankfurt, Germany 
in 1981.
12
 It was approved for the treatment of pain in 
1984 in Europe. However, it has never been approved by 
USFDA for any clinical use. Currently, flupirtine is sold 
under various brand name (Pruf & Vasfree by Intas 
Pharma, Lupirtin by Lupin Laboratories Ltd, etc ) in India. 
In 2010, the chemically related drug (the difference being 
that the pyridine group in flupirtine is replaced with a 
phenyl group) retigabine was approved by the FDA as an 
anticonvulsant for the treatment of partial seizures. 
PHARMACODYNAMICS  
Flupirtine is a nonopioid drug without antipyretic or 
antiphlogistic properties and has a favorable tolerability. 
The action of flupirtine does not depend on any central 
opioid effect because pain-relieving property of flupirtine 
is not reduced by naloxone, it does not induce any 
dependence or there is no need for a constant increase of 
the dose to maintain the clinical effect and it shows no 
relevant affinity to any of the known opiate receptors. 
Also, serotonin receptor antagonists do not inhibit the 
pain-relieving effect of flupirtine. There are no relevant 
affinities for α1- or α2-adrenoreceptors.13 
Analgesic action: It is a selective neuronal potassium 
channel opener that also has indirect N-methyl-d-aspartate 
(NMDA) receptor antagonist properties.
14
 The drug 
activates G-protein-coupled receptors that stimulate K+ 
channels of neuronal cells. Flupirtine inhibits neuronal 
excitability and reduce calcium Ca2+ influx into the cells. 
The mechanism is vital for neuronal transmission of pain 
Kumar et al                                                  Journal of Drug Delivery & Therapeutics; 2013, 3(6), 113-116    115 
© 2011, JDDT. All Rights Reserved                                                     ISSN: 2250-1177                                                        CODEN (USA): JDDTAO 
signals to motor neurons. Activation of this channel leads 
to hyperpolarization of neuronal membrane and the neuron 
becomes less excitable; thus, there is stabilization of 
resting neuronal membrane.
15
 This action inhibits the 
transmission of nociceptive impulses during neuronal 
excitation. 
Muscle relaxant action: The muscle relaxant action of 
flupirtine is due to inhibition of both mono- and 
polysynaptic reflexes. It possesses analgesic as well as 
muscle-relaxing effect in same dose ranges; thus, can be 
used in the treatment of painful diseases of the motor 
system presenting with spasticity and chronic 
musculoskeletal pain.
16 
Neuroprotective action: Flupirtine protects from 
apoptosis of neuronal cells which is caused by increased 
intracellular Ca ++ levels, mitochondrial dysfunction, cell 
membrane disruption and nucleolysis.
17
  It also increases 
the levels of Bcl-2 and glutathione in glutamate or NMDA-
induced apoptosis of human neurons as well as cultured 
retinal pigment cells.
15,17
 It reduces the expression of 
oncogenes and formation of reactive oxygen radicals in 
experimental models which explains its action of 
preventing ischemia-induced apoptosis. This explains that 
flupirtine has role treatment of neuroinfections such as 
immune deficiency syndrome (AIDS), prion diseases, and 
neurodegenerative disease such as Alzheimer's.
6 
Antiparkinsonian action: Flupirtine reduces muscular 
rigidity and increased the ability of L-DOPA to reverse 
akinesia.
18
 It, alone and in combination with L-DOPA 




Flupirtine is a water soluble compound and almost 
completely absorbed from gastrointestinal tract with a 
bioavailability of 90% by oral route and 70% by rectal 
route.
20
 It has large volume of distribution (Vd) and gets 
equally distributed into both extra and intravascular 
compartments. It is 80-84% bound to human albumin. 
Concentration in CSF is same as that in plasma and higher 
concentration was observed in liver and exocrine glands, 
whereas lower concentration was observed in the kidney.
21
 
The half-life of flupirtine on oral, intravenous and rectal 
administration with 100 mg is 6.5, 8.5 and 10.7 hr, 
respectively, in healthy volunteers. Biotransformation of 
flupirtine takes place in the liver. It is converted to two 
primary metabolites, p-fluoro-hippuric acid and an 
acetylated metabolite.
22
 The two metabolites are formed by 
oxidative degradation and acetylation of a hydrolysis 
product, respectively. The two metabolites are further 
oxidized and then conjugated with glycine to form inactive 
metabolites.
23
 Most of the total dose administered appears 
in urine whereas 18% is excreted in feces. 
Dosage and formulation-  Flupirtine can be administered 
by oral and rectal routes. It is available as 50 and 100 mg 
for oral administration. Adult dose is 300-400 mg per day 
in 3-4 divided dose and can be administered up to 600 mg 
per day. Dose in children is 150-200 mg per day in 3-4 
divided doses.
23,24
 Rectal suppositories are administered in 
the dose range of 450-600 mg per day in adults and 150-
250 mg per day in children.
24 
USES    
Flupirtine works as an analgesic for various types of acute 
and chronic pain like headache, trauma, migraine and 
gynaecology. Due to its muscle relaxant properties it is 
widely used for backache and other orthopaedic pain. Due 
to its neuroprotective action, it has possible applications in 
multiple sclerosis, Batten disease, Alzeimer’s disease and 
Creutzfeld- Jakob disease.
25,26
 It is very useful in reducing 
pain of fibromyalgia.
27
 It is also very effective in cancer 
and post operative pain. It is used in Parkinson’s disease as 
anticataleptic agent and also reverses muscle rigidity and 
akinesia. 
DRUG INTERACTIONS 
Flupirtine increases warfarin toxicity by unknown 
mechanism and hence, patients on oral anticoagulant 
therapy should be monitored for prothrombin time. It also 
increases hepatotoxic potential of paracetamol; thus, 
hepatic transaminases levels should be monitored when 
both the drugs are given concomitantly. Alcohol and other 
sedatives including benzodiazepines potentiate tiredness 
and dizziness due to flupirtine.
24
 Carbamazepine induces 
hepatic enzymes so should not be given together. 
SIDE EFFECTS 
Flupirtine is a safe drug and has high tolerability. Drug 
tolerance does not develop in most cases.
28 
Its side effects 
are dose dependant and divided into two categories.
29,30 
Peripheral Side Effects: Dryness of mouth, nausea, 
vomiting, constipation, blurring of vision, abdominal 
discomfort, heartburn, pruritus, hypotension, arrhythmias, 
atrial fibrillation, left bundle branch block, thrombocytosis, 
elevated liver enzymes, elevated blood urea nitrogen and 
serum creatinine. 
CNS Side Effects: Fatigue, headache, insomnia, 
weakness, sedation, tremor, anxiety, hallucination, 
disorientation, depression, etc. 
SAFETY PROFILE 
Flupirtine is notably devoid of any addictive properties, 
negative psychological or motor function effects, or effects 
on reproductive function. Drug tolerance does not develop 
in most cases.
28
 It can also be safely administered in 
diabetic and renal patients. Common side effects of 
flupirtine are dizziness, drowsiness, heartburn, dry mouth, 
nausea, elevated mood, fatigue, weakness, etc. which are 
mild and transient. Slight decreases in systolic blood 
pressure, elevation in liver enzymes, blood urea nitrogen 
and serum creatinine have been observed in some patients 




Safety of flupirtine in pregnant, lactating women and 
children less than 6 years is not clear. If indicated in 
lactating women, breastfeeding should be stopped. Dose 




Contraindications: Flupirtine should be avoided in 
patients with history of hypersensitivity to flupirtine, 
hepatic encephalopathy, cholestasis, myasthenia gravis, 
chronic alcoholism, primary biliary cirrhosis and other 
liver diseases. 
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Advantages over NSAIDs and OPIOIDs: NSAIDs and 
Opioids  are conventional analgesic drugs and are widely 
used for various pain management, but they are well 
known to produce worrisome adverse effects such as 
respiratory depression, tolerance and dependence that are 
typical of opioids,
31
 and gastrointestinal (epigastric pain, 
bleeding, perforation, obstruction, etc) and renal 
problems
32
 (nephropathy, interstitial nephritis, acute 
tubular necrosis, etc) associated with NSAIDS.  
CONCLUSION 
Many diseases present with symptom of pain as presenting 
complaint, so proper treatment of this symptom is of great 
significance. Flupirtine is effective analgesic for treatment 
of acute and chronic, mild to moderate pain states such as 
postoperative pain, traumatic injury, headache, migraine, 
musculoskeletal pain, cancer pain, orthopaedic and 
gynecological problems. It is equally effective but better 
tolerated than commonly used agents for these conditions. 
Its additional antiapoptotic, cytoprotective and antioxidant 
properties has usefulness in treatment of 
neurodegenerative diseases like Multiple sclerosis, Batten 
disease, Alzeimer’s disease, Creutzfeld- Jakob disease and 
Parkinson disease. It is well tolerated with mild and 
infrequent adverse effects. Minimal effects on 
gastrointestinal and renal system, respiration, and lack of 
tolerance or physical dependence, are added advantage 
over NSAIDs opioids.  
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